Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy

Basit Öğe Kaydı
dc.authoridTopkan, Erkan/0000-0001-8120-7123
dc.authoridselek, ugur/0000-0001-8087-3140
dc.authoridPehlivan, Umur Anil/0000-0001-5871-0695
dc.authoridYilmaz, Busra/0000-0003-0633-5648
dc.authoridSomay, efsun/0000-0001-8251-6913
dc.authorwosidTopkan, Erkan/AAG-2213-2021
dc.authorwosidselek, ugur/O-5474-2014
dc.contributor.authorPehlivan, Umur Anil
dc.contributor.authorSomay, Efsun
dc.contributor.authorYilmaz, Busra
dc.contributor.authorBesen, Ali Ayberk
dc.contributor.authorMertsoylu, Huseyin
dc.contributor.authorSelek, Ugur
dc.contributor.authorTopkan, Erkan
dc.date.accessioned2024-05-19T14:45:54Z
dc.date.available2024-05-19T14:45:54Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground and purpose: Muscle loss is a significant indicator of cancer cachexia and is associated with a poor prognosis in cancer patients. Given the absence of comparable studies, the current retrospective study sought to examine the correlation between the total masseter muscle volume (TMMV) before treatment and the survival outcomes in locally advanced nasopharyngeal cancer (LA-NPC) patients who received definitive concurrent chemoradiotherapy (CCRT). Methods: A three-dimensional segmentation model was used to determine the TMMV for each patient by analyzing pre-CCRT magnetic resonance imaging. The optimal TMMV cutoff values were searched using receiver operating characteristic (ROC) curve analyses. The primary and secondary endpoints were the relationship between the pre-CCRT TMMV measures and overall survival (OS) and progression-free survival (PFS), respectively. Results: Ninety-seven patients were included in this study. ROC curve analyses revealed 38.0 cc as the optimal TMMV cutoff: <= 38.00 cc (n = 42) and >38.0 cc (n = 55). Comparisons between the two groups showed that the TMMV>38.0 cc group had significantly longer PFS [Not reached (NR) vs. 28; p < 0.01] and OS (NR vs. 71; p < 0.01) times, respectively. The results of the multivariate analysis demonstrated that the T-stage, N-stage, number of concurrent chemotherapy cycles, and TMMV were independent associates of PFS (p < 0.05 for each) and OS (p < 0.05 for each) outcomes, respectively. Conclusion: The findings of the current retrospective research suggest that pretreatment TMMV is a promising indicator for predicting survival outcomes in LA-NPC patients receiving definitive CCRT.en_US
dc.description.sponsorshipBaskent University Adana Dr. Turgut Noyan Application and Research Centeren_US
dc.description.sponsorshipThe APC was funded by Baskent University Adana Dr. Turgut Noyan Application and Research Center.en_US
dc.identifier.doi10.3390/jcm12216863
dc.identifier.issn2077-0383
dc.identifier.issue21en_US
dc.identifier.pmid37959329en_US
dc.identifier.scopus2-s2.0-85176556621en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org10.3390/jcm12216863
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5388
dc.identifier.volume12en_US
dc.identifier.wosWOS:001103246100001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofJournal of Clinical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectMuscle Lossen_US
dc.subjectMasseter Muscleen_US
dc.subjectLocally Advanced Nasopharyngeal Canceren_US
dc.subjectChemoradiotherapyen_US
dc.subjectSurvivalen_US
dc.titlePretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu